Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 61
What CJC-1295 actually costs in the UK
CJC-1295 has no UK marketing authorisation, so there is no NHS price and no reimbursement. Here is what sets its grey-market cash cost.
CJC-1295 in the UK: the regulatory status
CJC-1295 holds no UK marketing authorisation and counts as an unlicensed medicine, so here is what the law says and what actually changed this year.
CJC-1295 import rules in the UK
CJC-1295 has no MHRA marketing authorisation, so UK medicines law leaves no ordinary route to import it as a medicine. Here is what the rules say.
Combining GLP-1 drugs and tesamorelin
No trial has tested combining retatrutide, tirzepatide and tesamorelin, and here is why doing so without clinical supervision is a real risk.
Do genes change how tirzepatide works?
A 2026 endocrinology review asks whether GLP-1 and GIP receptor gene variants help explain why people respond differently to tirzepatide and semaglutide.
FDA panel backs compounded BPC-157, KPV
An FDA advisory panel voted 8 to 6 to recommend that compounding pharmacies be allowed to prepare BPC-157 and KPV, two unapproved peptides.
FDA panel backs BPC-157 compounding
The FDA's PCAC voted narrowly on 23 July 2026 to recommend allowing compounding pharmacies to produce BPC-157, KPV, TB-500, and MOTS-c. The vote is non-binding.
GLP-1 telehealth oversight and rare disease
A STAT investigation alleged LifeMD reviewed GLP-1 prescriptions at 25 cases per hour, raising safety questions for a drug class with a boxed warning.
Retatrutide: Lilly plans FDA filing in 2027
New TRIUMPH data give Lilly the evidence to file an FDA application for retatrutide in Q1 2027. The cardiovascular outcomes question remains open.
Semaglutide for postpartum prediabetes
A Belgian trial is testing whether once-weekly semaglutide can stop postpartum prediabetes after gestational diabetes from becoming type 2 diabetes.
Semaglutide proteomics: 16 studies reviewed
A 2026 review of 16 proteomics studies maps what semaglutide does to proteins across human and animal tissues, from fat metabolism to cardiac remodelling.
What proteomics reveals about semaglutide
A 2026 review pooled 16 proteomics studies of semaglutide in humans and animals to map which proteins and pathways the drug shifts, and how much to trust it.